Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664903 | 0.86 | NPC1 (0.52) | TAAR1ALDH1A1NR0B1MEN1KMT2A | |
| SCHEMBL4665011 | 0.84 | SMN1; SMN2 (0.45) | ALDH1A1NR0B1MEN1KMT2AALOX5 | |
| SCHEMBL4662985 | 0.83 | RAB9A (0.46) | ALDH1A1NPC1RAB9A | |
| SCHEMBL4666680 | 0.82 | PLAAT3 (0.51) | HPGDALDH1A1KMT2AALOX5LMNA | |
| SCHEMBL4664915 | 0.81 | NPC1 (0.48) | ALDH1A1NR0B1MEN1KMT2AALOX5 | |
| SCHEMBL4666721 | 0.78 | GPR84 (0.41) | ALDH1A1NR0B1MEN1KMT2ALMNA | |
| SCHEMBL4244260 | 0.78 | KMT2A (0.54) | ALDH1A1NR0B1MEN1KMT2ALMNA | |
| SCHEMBL4666733 | 0.78 | CDK4 (0.47) | HPGDTAAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL4664683 | 0.78 | NR0B1 (0.45) | ALDH1A1NR0B1MEN1KMT2ALMNA | |
| SCHEMBL4241441 | 0.76 | NR0B1 (0.48) | ALDH1A1NR0B1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | claimed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | claimed |
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | disclosed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | BACE1, PSEN1, BACE2 | HPGD 4570/4885TAAR1 500/4885ALDH1A1 2826/4885 |
| US-20050119329-A1 | Tetronic and tetramic acids | BACE1, PSEN1, BACE2 | HPGD 4570/4885TAAR1 500/4885ALDH1A1 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.